L. Gaziano

Genome-wide association analysis and Mendelian randomization proteomics identify novel protein biomarkers and drug targets for primary prevention of heart failure

P. Munroe, J. Whittaker, G. Peloso, 2022, medRxiv.

Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19

Grant D. Huang, Yan V. Sun, J. Danesh, 2020, Nature Medicine.

Leveraging Population Genomics to Enhance Preventive Cardio-Oncology

K. Aragam, L. Gaziano, 2022, JACC. CardioOncology.

Rare and Common Genetic Variation Underlying the Risk of Hypertrophic Cardiomyopathy in a National Biobank.

P. Ellinor, S. Choi, S. Lubitz, 2022, JAMA cardiology.

Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses

James R. Staley, J. Danesh, R. Kronmal, 2022, Circulation.

Risk of stroke in relation to degree of asymptomatic carotid stenosis: a population-based cohort study, systematic review, and meta-analysis

P. Rothwell, L. Gaziano, D. Howard, 2021, The Lancet Neurology.

Risk factors and prediction models for incident heart failure with reduced and preserved ejection fraction

J. Danesh, A. Wood, J. Gaziano, 2021, ESC heart failure.

Genome-wide association analysis and Mendelian randomization proteomics identify drug targets for heart failure

María P. Magariños, Steffen E. Petersen, P. Munroe, 2023, Nature communications.